Join to view full profile
1515 Holcombe BlvdUnit 429Houston, TX 77030
Phone+1 713-792-2860
Fax+1 713-563-5067
Dr. Orlowski is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1994 - 1998
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1991 - 1994
Yale School of MedicineClass of 1991
Columbia College / Columbia UniversityBA, Chemistry, Magna Cum Laude, 1979 - 1983- Bronx High School of ScienceHigh School, 1976 - 1979
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2022 - 2027
GA State Medical License 2022 - 2027
MS State Medical License 2022 - 2027
TX State Medical License 2007 - 2027
AL State Medical License 2022 - 2026
LA State Medical License 2022 - 2026
American Board of Internal Medicine Medical Oncology- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013, 2015
- America's Top Doctors Castle Connolly, 2008-2014
- Top Doctors:SE Texas Castle Connolly, 2013
Clinical Trials
- Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
- Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
- Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients Start of enrollment: 2012 Jun 20
Publications & Presentations
PubMed
- Phase I/II Trial of Evomela for Autologous Transplant in Myeloma: Schedule Optimization and Matched Comparison with MEL200.Qaiser Bashir, Peter F Thall, Jitesh Kawedia, Xun Xu, Cristina G Knape
Blood Advances. 2026-07-31 - Activating RARβ to overcome immunomodulatory drug resistance in t(4;14) human myeloma.Ling Zhong, Qiang Wang, Miao Xian, Jianfei Qian, Chuanchao Zhang
Leukemia. 2026-07-30 - Prognostic impact of monosomy 13 and deletion of 13q in multiple myeloma patients undergoing upfront autologous transplantation.Damian M Mikulski, Curtis Marcoux, Mark R Tanner, Qaiser Bashir, Samer Srour
British Journal of Haematology. 2026-07-24
Journal Articles
- Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction DrugsKrina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature
- Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191Sheeba K Thomas, Robert Z Orlowski, Hans C Lee, Clinical Cancer Research
Abstracts/Posters
- A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)Clinically Relevant AbstractRobert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Amyloidosis and Waldenstr_m Macroglobulinemia (Part 2 of a 2-Part Series)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myel...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- African-American Patients with Monoclonal Gammopathy Have a Reduced Risk of Transformation to Clinical Myeloma: Results of a Prospective Study SWOG S01202018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Press Release: ASH: Sarclisa Combinations Demonstrated Significant Benefits in Newly Diagnosed Multiple Myeloma PatientsDecember 9th, 2024- Upfront Daratumumab Shows Survival Benefit in Combination for Transplant-Ineligible Multiple MyelomaSeptember 11th, 2021
- Asylia Announces Formation of Distinguished Scientific Advisory BoardJuly 22nd, 2021
Grant Support
- Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell LymphomasUNIVERSITY OF TX MD ANDERSON CAN CTR2022–2027
- P3 - Targeting The HDM-2 E3 Ligase In Multiple MyelomaNational Cancer Institute2010–2011
- M. D. Anderson Cancer Center Spore In Multiple MyelomaNational Cancer Institute2010–2011
- Developmental Research ProgramNational Cancer Institute2010–2011
- Administrative Core FacilityNational Cancer Institute2010–2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
